Related Experiment Video
Updated: Jun 27, 2026
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas
Toshihiro Matsuo1, Takashi Sugita, Shoji Shimose
1Department of Artificial Joints and Biomaterials, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. tomatsuo@hiroshima-u.ac.jp
Background:
The function of promyelocytic leukemia (PML) bodies is not well known but plays an important role in controlling cell proliferation, apoptosis and senescence. This study was undertaken to analyze the clinical significance of PML body expression in primary tumor samples from malignant fibrous histiocytoma (MFH) and liposarcoma patients.
Methods:
We studied MFH and liposarcoma samples from 55 patients for PML bodies. Fluorescent immunostaining of PML bodies was performed in the paraffin-embedded tumor sections.
Results:
PML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma samples. PML body expression rates of all sarcoma cells were 1.5 +/- 1.8% (range: 0-7.0) in MFH and 1.3 +/- 1.4% (0-5.2) in liposarcoma samples. PML body expression (p = 0.0053) and a high rate of PML body expression (p = 0.0012) were significantly greater prognostic risk factors for death than the other clinical factors in MFH patients. All liposarcoma patients without expression of PML were disease free at the end of the study.
Conclusion:
Our study suggests that the presence of PML bodies may indicate a poor prognosis for MFH and liposarcoma patients.
Insights
Promyelocytic leukemia (PML) bodies are linked to poor prognosis in patients with malignant fibrous histiocytoma (MFH) and liposarcoma. Their presence indicates a higher risk of mortality in MFH and disease recurrence in liposarcoma.
Area of Science:
- Oncology
- Cell Biology
- Cancer Research
Background:
- Promyelocytic leukemia (PML) bodies are nuclear structures with poorly understood functions.
- PML bodies are implicated in regulating cell proliferation, apoptosis, and senescence.
- This study investigates the clinical significance of PML body expression in specific sarcoma subtypes.
Purpose of the Study:
- To analyze the clinical significance of PML body expression in primary tumor samples.
- To determine the prognostic value of PML bodies in malignant fibrous histiocytoma (MFH) and liposarcoma.
Main Methods:
- Examined 55 patient samples of MFH and liposarcoma.
- Utilized fluorescent immunostaining on paraffin-embedded tumor sections to detect PML bodies.
Main Results:
- PML body expression was detected in 63.9% of MFH and 63.2% of liposarcoma samples.
- Higher rates of PML body expression were significant prognostic risk factors for death in MFH patients (p = 0.0012).
- Liposarcoma patients without PML expression remained disease-free, suggesting a favorable prognosis.
Conclusions:
- The presence of PML bodies may indicate a poor prognosis for both MFH and liposarcoma patients.
- PML body expression serves as a potential biomarker for predicting patient outcomes in these sarcomas.
